Flag of the European Union EU Clinical Trials Register Help

Clinical trials for stem cell therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7292   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    921 result(s) found for: stem cell therapy. Displaying page 1 of 47.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-004928-21 Sponsor Protocol Number: Auto-Allo-TSCTinMM Start Date*: 2008-06-27
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study
    Medical condition: Multiple Myeloma Stage II or III according to Salmon and Durie
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000393-76 Sponsor Protocol Number: ZKI-SCT-HAPLO-0106 Start Date*: 2006-10-25
    Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt am Main
    Full Title: Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical related and non-related donators in pediatric patients with and without malignant systemic diseases.
    Medical condition: Pediatric patients with malignant and non-malignant high-risk diseases, where the allogeneic stem cell transplantation represents the only option for a curative therapy and where an adequate HLA-id...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002657-45 Sponsor Protocol Number: MSC1 Start Date*: 2005-10-24
    Sponsor Name:Cardiovascular laboratory 2014, Rigshospitalet
    Full Title: Mesenchymal stem cell therapy in patients with severe myocardial ischemia
    Medical condition: Chronic coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004499-47 Sponsor Protocol Number: ZENITH Start Date*: 2015-04-16
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A case control, phase II, monocentric, randomized study, utilizing Zinc as enhancer of immune recovery and immune reconstitution in auto-transplant for multiple myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001514-34 Sponsor Protocol Number: ILNK15-01 Start Date*: 2012-04-03
    Sponsor Name:Leiden University Medical Center
    Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study
    Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10023685 LAK cell therapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000873-59 Sponsor Protocol Number: Uni-Koeln-3263 Start Date*: 2019-06-13
    Sponsor Name:University of Cologne
    Full Title: Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
    Medical condition: disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001005-67 Sponsor Protocol Number: AlloRelapseMMStudy Start Date*: 2022-05-11
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005562-38 Sponsor Protocol Number: M2011-238 Start Date*: 2012-11-13
    Sponsor Name:Miltenyi Biotec GmbH
    Full Title: A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in chi...
    Medical condition: Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004953-26 Sponsor Protocol Number: BHS-TC13 Start Date*: 2016-03-11
    Sponsor Name:Ghent University Hospital
    Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000015-24 Sponsor Protocol Number: 07MI05 Start Date*: 2015-04-10
    Sponsor Name:Great Ormond Street Hospital
    Full Title: 90-Yttrium-labelled anti-CD66 monoclonal antibody as part of a reduced intensity conditioning regimen prior to allogeneic haematopoietic stem cell transplantation: an open label, dose escalating ph...
    Medical condition: High risk relapsed or refractory leukaemia in childhood
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001911-38 Sponsor Protocol Number: GELTAMOMAN2 Start Date*: 2014-09-19
    Sponsor Name:Grupo Español de Linfoma y Trasplante Autólogo de Médula ósea
    Full Title: AN OPEN MULTICENTER PHASE II STUDY OF EFFICACY AND TOXICITY OF MAINTENANCE SUBCUTANEOUS RITUXIMAB AFTER RESCUE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FO...
    Medical condition: PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FOR AUTO OR ALLO STEM CELL TRANSPLANTATION
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026803 Mantle cell lymphoma stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000290-23 Sponsor Protocol Number: HULPVAS-2011-01 Start Date*: 2013-02-06
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz
    Full Title: Clinical trial phase IIa to safety treating critical ischemia non-revascularizable lower limb by mesenchymal stem cells.
    Medical condition: Treatment of critical limb ischemia non-revascularization by mesenchymal stem cells.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001790-86 Sponsor Protocol Number: PIX306 Start Date*: 2012-12-24
    Sponsor Name:CTI Biopharma, Corp.
    Full Title: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or a...
    Medical condition: Treatment of Patients with Aggressive B-cell Non-Hodgkin Lymphoma , who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    19.1 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) HU (Completed) IT (Completed) CZ (Completed) DK (Prematurely Ended) BG (Prematurely Ended) PL (Completed) BE (Completed) AT (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-012437-30 Sponsor Protocol Number: BUS‐2009/01 Start Date*: 2010-06-17
    Sponsor Name:Skånes University Hospital
    Full Title: Clofarabine based remission induction followed by haploidentical stem cell transplantation in children with refractory hematological malignancies
    Medical condition: Therapy resitant leukemia in children and young adults
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003683-54 Sponsor Protocol Number: OSHO #76 Start Date*: 2008-06-18
    Sponsor Name:GMIHO Gesellschaft für medizinische Innovation/Hämatologie und Onkologie mbH
    Full Title: Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Granzkörperbest...
    Medical condition: Patients suffering from leukemia (acute or chronic), receiving allogenic blood stem cell transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000795-15 Sponsor Protocol Number: MYVAC2 Start Date*: 2014-01-29
    Sponsor Name:UZ Brussel
    Full Title: An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after f...
    Medical condition: Symptomatic Multiple Myeloma after first-line autologous stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003033-42 Sponsor Protocol Number: UKER-BLZ-PH1 Start Date*: 2013-09-12
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prospective, open-label, multicentre clinical trial, phase I/IIa, to investigate the safety and tolerability of allogeneic B-cell concentrates CD3+-depleted, CD19+-enriched, cryopreserved (single a...
    Medical condition: Status post allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10067862 Allogeneic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001117-34 Sponsor Protocol Number: APL-B-013-02 Start Date*: 2004-10-13
    Sponsor Name:Pharma Mar S.A.
    Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.
    Medical condition: Aggressive non-Hodgkin’s Lymphoma.For aggressive NHL patient cure is still the target of therapy and a CR is a prerequisite to achieve this goal. Salvage therapy needs more aggressive experimental ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024307-27 Sponsor Protocol Number: LUMC2010-03 Start Date*: 2011-11-01
    Sponsor Name:Leiden University Medical Center
    Full Title: TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
    Medical condition: CMV reactivation after allogeneic stem cell transplantation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003523-30 Sponsor Protocol Number: 38RC17.191 Start Date*: 2017-12-18
    Sponsor Name:University Hospital Grenoble
    Full Title: Vaccination after hematopoietic stem cell transplantation : a randomized study estimating the interest of an additional injection for patients not reponding at M3.
    Medical condition: Our aim is to determine whether an additional dose of inactivated vaccine can increase the rate of responders among patients who have not responded adequately after 3 injections
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 07 07:36:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA